



Novel Melatonin Based Therapies

Guest Editors:

**Prof. Dr. Alejandro Romero
Martínez**

Department of Pharmacology
and Toxicology, Faculty of
Veterinary Medicine,
Complutense University of
Madrid, Avda. Puerta de Hierro
s/n, 28040 Madrid, Spain

Prof. Dr. Russel J. Reiter

Department of Cellular &
Structural Biology, The UT Health
Science Center, 7703 Floyd Curl
Drive, San Antonio, TX 78229-
3900, USA

Prof. Dr. Germaine Escames

Health Sciences Technology
Park, Universidad de Granada,
18071 Granada, Spain

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editors

Dear Colleagues,

Melatonin has emerged in the last decade as a promising agent to counteract most of the physiopathological events that trigger several disorders. Most of the beneficial molecular functions exerted by melatonin are due to the following: Its small size and amphiphilic nature allow the molecule to easily diffuse through any membrane, reaching cytosolic, mitochondrial and nuclear compartments. It is a potent scavenger of free radicals, both directly and indirectly, inhibiting the activity of prooxidative enzymes and stimulating antioxidant enzymes through interactions with two high-affinity G protein-coupled receptors.

In this Special Issue, we will focus on the use of melatonin as an adjuvant treatment in a wide variety of diseases, which could be of critical importance for the development of novel therapeutic strategies.

This Special Issue will serve as a forum to bring together researchers of different fields to share advances in the knowledge of the therapeutic uses of melatonin.

Prof. Dr. Alejandro Romero Martínez

Prof. Dr. Russel J. Reiter

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

Contact Us

Diseases Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diseases
diseases@mdpi.com
X@Diseases_MDPI